Craig-Hallum Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $12

Alteriry Therapeutics Ltd Sponsored ADR

Alteriry Therapeutics Ltd Sponsored ADR

ATHE

0.00

Craig-Hallum analyst Adam Vogel initiates coverage on Alterity Therapeutics (NASDAQ: ATHE) with a Buy rating and announces Price Target of $12.